Dermot Mark Durcan bought $1.1M of Cencora (COR)
Executed Jun 18, disclosed Jun 22, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 22), the stock returned +11.2% (delay-adjusted); from the execution session (Jun 18), +9.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Dermot Mark Durcan (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Cencora, Inc. (COR). Across 2 priced purchase filings, the average 21-session return was +8.2% from execution and +8.9% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of COR (4,000 sh × $274.19, as filed), executed Jun 18.
Healthcare · Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→4,000 sh × $266.26
Exec May 28
Filed May 28 · 4:23 PM ET